Alvah T Wickboldt is a notable inventor based in New Orleans, LA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the modulation of leukotriene A4 hydrolase. With a total of 2 patents, his work has implications for treating various disease states and disorders.

Latest Patents

Wickboldt's latest patents include compounds such as thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines. These compounds are recognized as effective modulators of leukotriene A4 hydrolase (LTA4H). They hold potential for use in pharmaceutical compositions and methods aimed at modulating LTA4H activity, which is crucial for addressing conditions mediated by this enzyme.

Career Highlights

Wickboldt is currently associated with Janssen Pharmaceutica NV, where he continues to advance his research and development efforts. His work is characterized by a focus on innovative solutions in the pharmaceutical industry, particularly in the area of enzyme modulation.

Collaborations

Throughout his career, Wickboldt has collaborated with esteemed colleagues such as Genesis M Bacani and Eugene Y Cheung. These partnerships have contributed to the depth and breadth of his research endeavors.

Conclusion

Alvah T Wickboldt stands out as a significant figure in the realm of pharmaceutical innovation. His contributions to the modulation of leukotriene A4 hydrolase through his patented compounds are paving the way for new treatment options.

This text is generated by artificial intelligence and may not be accurate.